Menu
29/06/2006
Obesity pill launched in the UK
A weight-loss drug, which is claimed to reduce bodyweight by as much as 10%, is being launched in the UK.
Rimonabant, which is sold under the brand name Acomplia, the first drug to target the areas of the body which control appetite, metabolism and energy use.
It is currently used to treat obese patients, or overweight patients with other conditions such as type 2 diabetes or poor cholesterol.
There is also evidence to suggest that it could help people quit smoking by combating nicotine cravings.
In a series of trials, involving more than 6,000 patients in the US and Europe, it was found that a quarter of participants lost more than 10% of their initial body weight after a year, while around half lost more than 5%.
However, concerns have been raised about the cost of the drug. The drug would cost just over £55 per patient per month, which could potentially cost the NHS billions.
The NHS Confederation stressed that weight loss was predominately about a healthy diet and regular exercise.
However, the manufacturers of Rimonabant, Sanofi Aventis, said that the drug was good value for money, especially when considered against the £7 billion annual cost of tackling problems caused by obesity.
The National Institute for Health and Clinical Excellence is not expected to issue a review on the use of Rimonabant for another two years, so widespread use of the drug is unlikely to happen until then.
(KMcA)
Rimonabant, which is sold under the brand name Acomplia, the first drug to target the areas of the body which control appetite, metabolism and energy use.
It is currently used to treat obese patients, or overweight patients with other conditions such as type 2 diabetes or poor cholesterol.
There is also evidence to suggest that it could help people quit smoking by combating nicotine cravings.
In a series of trials, involving more than 6,000 patients in the US and Europe, it was found that a quarter of participants lost more than 10% of their initial body weight after a year, while around half lost more than 5%.
However, concerns have been raised about the cost of the drug. The drug would cost just over £55 per patient per month, which could potentially cost the NHS billions.
The NHS Confederation stressed that weight loss was predominately about a healthy diet and regular exercise.
However, the manufacturers of Rimonabant, Sanofi Aventis, said that the drug was good value for money, especially when considered against the £7 billion annual cost of tackling problems caused by obesity.
The National Institute for Health and Clinical Excellence is not expected to issue a review on the use of Rimonabant for another two years, so widespread use of the drug is unlikely to happen until then.
(KMcA)
Related UK National News Stories
Click here for the latest headlines.
25 June 2008
Controversial Weight Loss Drug Available For NHS Use
Despite fears of an increased risk of depression and possible suicide as a 'side-effect', a controversial anti-obesity drug has been made available for NHS use.
Controversial Weight Loss Drug Available For NHS Use
Despite fears of an increased risk of depression and possible suicide as a 'side-effect', a controversial anti-obesity drug has been made available for NHS use.
25 September 2015
Further Six Arrested In No Deal Operation In Birmingham
A further six people have been arrested as part of an ongoing operation targeting suspected drug dealers in Birmingham. Police carried out a series of dawn raids on Thursday 24 September, arresting a 17-year-old man, two 19-year-olds and three men aged 21, 26 and 47.
Further Six Arrested In No Deal Operation In Birmingham
A further six people have been arrested as part of an ongoing operation targeting suspected drug dealers in Birmingham. Police carried out a series of dawn raids on Thursday 24 September, arresting a 17-year-old man, two 19-year-olds and three men aged 21, 26 and 47.
17 October 2003
54 arrested in swoop on suspected drug dealers
Sellers of the Big Issue were among 54 people arrested by Merseyside Police today in a crackdown on drug dealing in Liverpool city centre. Operation Manton targeted suspected drug dealers and drug users and 50 men and four women were arrested following a 15-month long investigation by Merseyside Police into drug dealing on the city's streets.
54 arrested in swoop on suspected drug dealers
Sellers of the Big Issue were among 54 people arrested by Merseyside Police today in a crackdown on drug dealing in Liverpool city centre. Operation Manton targeted suspected drug dealers and drug users and 50 men and four women were arrested following a 15-month long investigation by Merseyside Police into drug dealing on the city's streets.
22 September 2008
Scottish Government Pledges Cap On Surgery Waiting Times
Scottish patients may soon have a legal guarantee that they will wait no longer than 12 weeks for surgery. The Scottish Government's Patient Rights Bill proposes a strict limit on how long they have to wait from their surgical referral to receiving their operation.
Scottish Government Pledges Cap On Surgery Waiting Times
Scottish patients may soon have a legal guarantee that they will wait no longer than 12 weeks for surgery. The Scottish Government's Patient Rights Bill proposes a strict limit on how long they have to wait from their surgical referral to receiving their operation.
31 August 2012
Heroin And Morphine Drug Deaths Fall
Heroin and morphine are still the substances most commonly involved in drug poisoning deaths, according to The Office for National Statistics. In 2011 there was a 25 per cent drop in fatalities, with 596 deaths.
Heroin And Morphine Drug Deaths Fall
Heroin and morphine are still the substances most commonly involved in drug poisoning deaths, according to The Office for National Statistics. In 2011 there was a 25 per cent drop in fatalities, with 596 deaths.
-
Northern Ireland WeatherThis Evening and Tonight:Showers will gradually die out during the evening. A cold night with long clear spells leading to a touch of frost in places. Light winds. Minimum temperature 0 °C.
